drugset
drugset / Trial / NCT04847544

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

NCT04847544 ↗

Phase 2 Completed 11 enrolled Aldeyra Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of ADX-629 Administered Orally for the Treatment of COVID-19

Timeline

Start
2021-03-31
Primary completion
2021-10-15
Completion
2021-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ACLOPROXALAP Other / unclassified 300 mg Oral

Indications

COVID-19